UK MHRA moves to risk-based GCP inspection model
This article was originally published in SRA
The UK Medicines and Healthcare products Regulatory Agency has adopted a new risk-based model for good clinical practice inspections under which the scope and frequency of inspections will depend on how an organisation takes responsibility for compliance with the regulations1,2.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.